No Data
Dizal Pharmaceutical's Shuvozhe Tablets Study Data Selected for Inclusion in ESMO Congress Report
Subgroup Analysis From Pivotal WU-KONG1B Study Exhibits Robust Efficacy of Sunvozertinib in Non-Small Cell Lung Cancer Patients With EGFR Exon 20 Insertion Mutations Across Different Baseline Characteristics
DiZhe Medicine (688192.SH): Subuozhe has demonstrated strong and lasting anti-tumor efficacy and good safety in the treatment of non-small cell lung cancer.
In a recent announcement, Dejia Medicine (688192.SH) stated that the company participated in the 2024 European Society for Medical Oncology (ESMO)...
Digel Pharmaceuticals: 2024 Semi-Annual Report
Digel Pharmaceuticals: 2024 Semi-Annual Report Summary
Di Zhe Pharmaceuticals (688192.SH): net loss of 0.345 billion yuan in the first half of the year.
On August 29th, Dezhe Medicine (688192.SH) released its 2024 semi-annual report, with the company's revenue for the reporting period at 0.204 billion yuan; the net loss attributable to shareholders of the listed company narrowed to 0.345 billion yuan; the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses narrowed to 0.381 billion yuan; the basic loss per share was 0.83 yuan/share.
No Data
No Data